Saturday, April 13, 2019 12:47:06 PM
Well, that combination would be, for me, a prime therapeutic goal; something to be focused on. First, of course, in transgenic murines (lab rats, with inserted genes of human central nervous system diseases; then, as quickly as possible, in human trials.
Why? The safety and multiple efficacies of Anavex 2-73 are so clearly established in transgenic murines that the three consequent human trials are proceeding, Rett syndrome (a 15-n, short human trial), Parkinson’s disease, and the final full-scale Altzheimer’s clinical trial involving 450 Australians.
But, then, what about Anavex 3-71? Simply, it either parallels or exceeds the positive therapeutic outcomes of Anavex 2-73 for various, multiple CNS diseases (and very likely others, where mitochondrial dysfunction is causative or complicating). A bit of the unique therapeutic traits of Anavex 3-71 are touched upon here: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147390529
But do one’s own diligence on the subject. In a browser read what comes up with this search:
anavex 3-71 advantages
Combining both of these powerful Anavex sigma-1 receptor agonists is likely to yield, at least, the favorable outcomes of one of the two. In combination there may well be a therapeutic synergy, where 1 + 1 = >2.
It’s not something difficult to assess with murines. I’m certain that Anavex Life Sciences Corp has data on such trials; but holding them for propitious revelation sometime in the future — perhaps after positive, confirming results emerge from any of the three human Anavex 2-73 trials underway.
Might all of this be clinical gamesmanship by Dr. Missling, setting in place some really spectacular murine results to be released after the three clinical trials establish Anavex 2-73 safety and efficacies in real humans? The big headlines from those, later this year, will be in the nature of, “New Anavex Drug Demonstrates Safety, Efficacy Against Three CNS Diseases.”
That will be really great. But what will be the results of a consequent media release by Anavex with a paragraph lead such as this:
“Anavex Life Sciences Corp is extremely pleased with the very positive therapeutic results Anavex 2-73 has proven in three clinical trials. We will now move forward with new clinical trials for a number of diseases caused by or involved with mitochondrial and autophagy dysfunctions. We have extensive murine data showing that duel administration of both Anavex 2-73 and Anavex 3-71 yields remarkable preventions and resolutions of a wide variety of human diseases with those involvements. We see this duel drug administration taking Anavex Life Sciences Corp to an even greater role as a major pharmaceutical corporation, treating or preventing an ever-wider diversity of diseases and conditions — as demonstrated in our extensive studies with transgenic murines.”
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM